Humira (adalimumab) / AbbVie 
Welcome,         Profile    Billing    Logout  
 200 Diseases   191 Trials   191 Trials   19915 News 


«12345678910111213...203204»
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Expanding Differential Ion Mobility Separations into the MegaDalton Range. (Pubmed Central) -  Apr 10, 2024   
    In the initial evaluation, the oligomers of monoclonal antibody adalimumab (148 kDa) are size-selected up to at least the nonamers (1.34 MDa) with m/z values up to ?17,000. This demonstrates the survival and efficient separation of noncovalent MDa assemblies in the FAIMS process, opening the door to novel analyses of the heaviest macromolecules.
  • ||||||||||  Rinvoq (upadacitinib) / AbbVie, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
    Health system specialty pharmacy: Ensuring continuity of care during provider transitions () -  Apr 9, 2024 - Abstract #AMCP2024AMCP_154;    
    HSSP teams successfully provided conti- nuity of care during a transitional period for patients with rheumatologic conditions. Because of their high-touch care, patients were not lost to follow-up and did not report increased symptoms during this period.
  • ||||||||||  Hadlima (adalimumab-bwwd) / Organon, Biogen, Samsung, Mundipharma, Yuhan Corp, Humira (adalimumab) / AbbVie
    Adalimumab-bwwd, a biosimilar of adalimumab, has the potential for substantial cost savings when prescribed () -  Apr 9, 2024 - Abstract #AMCP2024AMCP_152;    
    In a scenario based on publicly available pricing, substantial cost savings were generated from switching patients to adalimumab-bwwd. As confirmed by real-world experience of other biosimilar adoption in the United States, the magnitude of these savings is dif- ficult to predict because of invisible rebate structures but adoption of biosimilars would inevitably realize substan- tial savings to plans.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
    Observational data, Journal:  An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis. (Pubmed Central) -  Apr 9, 2024   
    The use of systemic corticosteroids and immunosuppressive/biologics was necessary for a high number of patients with noninfectious uveitis. In our series, tocilizumab was significantly more effective in the resolution of macular edema.
  • ||||||||||  Humira SC (adalimumab/hyaluronidase) / AbbVie, Humira (adalimumab) / AbbVie
    Precision immunomodulation: Adalimumab and Immunoglobulin replacement therapy in treating autoimmune complications of Inborn Errors of Immunity (Sevilla; Channel Sevilla) -  Apr 5, 2024 - Abstract #EAACI2024EAACI_969;    
    Previous attempts to address the condition with steroid and methotrexate proved ineffective...Following the diagnosis of Common Variable Immunodeficiency (CVID) according to the ESID criteria, the implementation of replacement therapy with facilitated subcutaneous Immunoglobulin (fSCIg, Hyqvia 20 g/month) significantly reduced the frequency of infectious recurrences...Subsequently, treatment with subcutaneous adalimumab (40 mg sc/2 weeks) was initiated, resulting in effective control of low back pain without exacerbating infections. Conclusions We observed that incorporating Adalimumab into the treatment regimen with facilitated subcutaneous Immunoglobulin (fSCIg) was both medically safe and beneficial for patients with psoriatic spondylarthritis and Crohn's-like colitis associated with Inborn Errors of Immunity and hypogammaglobulinemia phenotype.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation. (Pubmed Central) -  Apr 4, 2024   
    Results from this Delphi study clearly show an overall consensus on the use of adalimumab in the management of PsO and PsA, particularly as first-choice for specific subpopulations (uveitis, IBD, hidradenitis suppurativa). Considering the cost-effectiveness of biosimilars within Italy, adalimumab may represent an effective and safe first-line treatment for patients with moderate-to-severe PsO or PsA, and a valid choice for switching after failure.
  • ||||||||||  Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
    PLASMA CELL-DIRECTED THERAPY IN A PATIENT WITH ANCA-NEGATIVE PAUCI-IMMUNE GLOMERULONEPHRITIS AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (Poster Tour 1) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2702;    
    We here present a patient with monoclonal gammopathy of undetermined significance (MGUS) who exhibited pauci-immune crescentic glomerulonephritis and responded to bortezomib despite the absence of monoclonal deposition...The evaluation for clinical unresponsiveness revealed spondyloarthropathy and MGUS, and adalimumab was initiated...Figure 1. Learning points for clinical practice: In patients with ANCA-associated vasculitis refractory to rituximab and cyclophosphamide, we suggest investigating MGUS and considering plasma-directed therapy as a potential treatment.
  • ||||||||||  tofacitinib / Generic mfg.
    TOFACITINIB IN THE MANAGEMENT OF REFRACTORY ADULT-ONSET STILL'S DISEASE WITH SYSTEMIC AND ARTHRITIC PHASES: TWO CASE REPORTS (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2575;    
    About 30% are refractory to conventional therapy with corticosteroids and conventional synthetic disease-modifying antirheumatic drugs, including methotrexate and cyclosporine...Patient 2 presented a chronic overlapping pattern, with systemic and chronic erosive arthritis course, also had an insufficient response to corticosteroids, methotrexate-leflunomide, and adalimumab...The patient 1 completed 2 years with therapy, while patient with chronic arthritis completed 3.8 years with tofacitinib therapy. The results support that tofacitinib can be effective for patients refractory to conventional treatment and contribute to disease remission.
  • ||||||||||  A CASE OF WHIPPLE DISEASE (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2574;    
    Learning points for clinical practice: Consider Whipple disease in patients with seronegative, non deforming, migrating arthritis non responsive to immunosuppression. Antibiotic therapy leads to rapid improvement in association with steroids to prevent IRIS.
  • ||||||||||  Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim
    RISANKIZUMAB EFFICACY IN SAPHO SYNDROME: A CASE REPORT ON RHEUMATOLOGIC AND DERMATOLOGIC DISEASE MANIFESTATIONS (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2572;    
    reported RIS efficacy on skin symptoms only in a single SAPHO patient, treated with colchicine and steroids too...She was previously treated with Methotrexate, Infliximab and Adalimumab and had an allergic reaction to Secukinumab...Health related QoL improved as early as week 16, particularly in physical functioning, pain and general health. In conclusion, IL-23p19 targeted therapy RIS can be considered a novel treatment option for SAPHO, especially for patients that had already been treated with other biologics.
  • ||||||||||  Humira (adalimumab) / AbbVie, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
    RHEUMATOID ARTHRITIS LEADS TO SEXUAL DYSFUNCTION AND REDUCED SEXUAL WELL-BEING EVEN IN THE ERA OF TARGETED TREATMENTS  (PARE Poster Tour) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_2230;    
    The existing literature did not conclusively determine whether the introduction of targeted drugs and the "treat-to-target" strategy has improved sexual well-being of RA patients. Despite the frequent deterioration in the sexual health of patients with RA, rheumatologists most often did not spontaneously address this aspect during consultations, emphasizing the importance of communication and education tools for both patients and caregivers.
  • ||||||||||  Tyenne (tocilizumab biosimilar) / Fresenius Kabi, Humira (adalimumab) / AbbVie, Rituxan (rituximab) / Roche
    COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB BIOSIMILAR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SPAIN (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1987;    
    Cost-effectiveness analysis using a Markov model including the following health states: remission of the disease, low activity, moderate activity, high activity, and death; with a lifetime horizon and abatacept, adalimumab, baricitinib, certolizumab, etanercept, filgotinib, golimumab, infliximab, rituximab, sarilumab, biological tocilizumab, tofacitinib, and upadacitinib as the comparators... Tocilizumab biosimilar proved to be a cost-effective and a cost-saving alternative for the treatment of patients with rheumatoid arthritis in Spain when compared to all the available biological or targeted synthetic DMARDs therapeutic alternatives.
  • ||||||||||  Humira (adalimumab) / AbbVie
    COMPARABLE SAFETY AND EFFECTIVENESS AMONG NEW USERS OF BIOSIMILAR VS ORIGINATOR ANTI-TNFS IN INFLAMMATORY ARTHRITIS: POPULATION-BASED EVIDENCE FROM A POLICY CHANGE (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1730;    
    Outcomes included severe infections (hospitalization with infection diagnostic code in any position); mild infections (oral/IV antibiotics without hospitalization); number of hospitalizations (any cause), physician and emergency department visits; hospital length of stay; and use of IA medications (daily dose, cumulative dose, proportion of follow-up days on drug, and number (%) of baseline users who discontinued and baseline non-users who initiated methotrexate (MTX) and glucocorticoids (GC)). Real-world population-based data showed that incident users of biosimilar etanercept and infliximab did not have higher rates of infections, HRU and use of IA medications compared to originators, suggesting comparable safety and effectiveness for IA and no unintended adverse consequences from the health policy.
  • ||||||||||  BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS SURVIVAL IN LATE-ONSET AXIAL SPONDYLOARTHRITIS  (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1656;    
    Although Lo-axSpA itself was not a significant factor in predicting drug discontinuation, age at disease onset was associated with a higher risk of discontinuation. Additionally, HLA-B27 absence, female gender and higher BMI were also linked to a higher risk of therapy discontinuation.
  • ||||||||||  Remicade (infliximab) / J&J, Actemra IV (tocilizumab) / Roche, JW Pharma, Humira (adalimumab) / AbbVie
    LONG TERM FOLLOW-UP OF CHILDREN WITH UVEITIS: SINGLE-CENTRE EXPERIENCE FROM NORTH INDIA (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1570;    
    Idiopathic uveitis constitutes the majority of patients. Amongst the non-infectious causes, JIA is the most common while tubercular uveitis is the most common infective cause.
  • ||||||||||  Humira (adalimumab) / AbbVie
    STRATIFICATION OF PEDIATRIC SAPHO SYNDROME BASED ON SKIN MANIFESTATIONS: RESULTS FROM AN ITALIAN MULTICENTRIC STUDY (SAPHOPED) (Poster View) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1560;    
    This study confirms the presence of 2 different disease clusters in pSAPHO based on the skin manifestations: an acne-HS-PG group characterized by a male predominance with puberal disease onset with skin manifestations particularly refractory to treatments, and a PPP-PV group characterized by female predominance with prepuberal disease onset with osteoarticular manifestations. These findings warrant a different therapeutical approach based on skin manifestations, and highlight the need of a new disease classification.